Direct letters to relatives at risk of hereditary cancer—study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study)
Carolina Hawranek(Umeå University), Anna Rosén(Unknown), Hans Ehrencrona(Lund University), Barbro Numan Hellquist(Umeå University), Anna Öfverholm(Swedish Institute)
Cited by 6
Related Papers
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|507
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i>
|JNCI Journal of the National Cancer Institute|2020|163
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
|PLoS Genetics|2014|130
Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility
|Genetics in Medicine|2017|93
Public support for healthcare-mediated disclosure of hereditary cancer risk information: Results from a population-based survey in Sweden
|Hereditary Cancer in Clinical Practice|2020|44